Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
9.41
0.36 (3.98%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :31,020
Date :11-22-2017
* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

November 14th, 2017|

JERUSALEM, Nov. 14, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel’s Ministry of Health has granted the […]

Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

October 31st, 2017|

JERUSALEM, Oct. 31, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed […]

Oramed to Present at the Diabetes Technology Meeting

October 24th, 2017|

JERUSALEM, October 24, 2017 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 17th […]

Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists

October 17th, 2017|

JERUSALEM, Oct. 17, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the publication of a new paper co-authored by Oramed’s […]